The New Scientist report details a Duke University mouse study where muscle stem cells from old rodents were extracted, supplemented with palmitate and oleate lipids to address glutaminase deficiency, and reinjected, yielding 45% larger muscle fibers and improved treadmill performance in injured legs. This ex vivo reboot bypasses systemic delivery risks, such as oncogenesis from unchecked lipid metabolism seen in cancer cells. However, the coverage underplays the study's limitations: small sample sizes typical of rodent models, short-term observation windows, and lack of long-term data on fibrosis or immune rejection. Synthesizing with related work, a 2023 Cell Stem Cell paper on metabolic reprogramming in aged satellite cells reinforces the lipid-enzyme axis, while Longeveron's Phase 2 trial (NCT04611347) of allogeneic mesenchymal stem cells showed modest 6-minute walk test gains in frail elderly patients, highlighting a pattern where autologous versus allogeneic approaches trade personalization for scalability. This ties into broader biotech trends like CRISPR-edited iPSC therapies and senolytics, positioning stem cell rebooting as a bridge to personalized regenerative medicine for sarcopenia and post-injury recovery, though human translation demands rigorous GMP protocols absent in current preclinical data.